Article info

Original research
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

Authors

  1. Correspondence to Dr Taofeek K Owonikoko; towonik{at}emory.edu
View Full Text

Citation

Pakkala S, Higgins K, Chen Z, et al
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

Publication history

  • Accepted November 15, 2020
  • First published December 21, 2020.
Online issue publication 
December 21, 2020
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.